| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
|
N Engl J Med
|
2010
|
8.77
|
|
2
|
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
|
Blood
|
2008
|
6.39
|
|
3
|
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
|
J Clin Oncol
|
2003
|
2.41
|
|
4
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
Blood
|
2012
|
2.32
|
|
5
|
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Blood
|
2008
|
2.31
|
|
6
|
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
|
Cancer
|
2004
|
2.30
|
|
7
|
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia.
|
Blood
|
2007
|
2.11
|
|
8
|
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
|
Blood
|
2002
|
1.87
|
|
9
|
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
Blood
|
2009
|
1.82
|
|
10
|
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
|
Br J Haematol
|
2007
|
1.76
|
|
11
|
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
|
Blood
|
2003
|
1.76
|
|
12
|
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
|
Blood
|
2003
|
1.72
|
|
13
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
Blood
|
2003
|
1.57
|
|
14
|
Adolescent and young adult oncology. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2012
|
1.55
|
|
15
|
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
|
J Clin Oncol
|
2002
|
1.52
|
|
16
|
Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.
|
J Exp Med
|
2011
|
1.49
|
|
17
|
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
|
Blood
|
2002
|
1.45
|
|
18
|
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
|
Blood
|
2013
|
1.42
|
|
19
|
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
|
Clin Cancer Res
|
2002
|
1.42
|
|
20
|
CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis.
|
Leuk Lymphoma
|
2013
|
1.38
|
|
21
|
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
|
J Clin Oncol
|
2004
|
1.28
|
|
22
|
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.26
|
|
23
|
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
|
Blood
|
2002
|
1.25
|
|
24
|
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.
|
Blood
|
2008
|
1.25
|
|
25
|
Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.
|
Am J Clin Pathol
|
2012
|
1.24
|
|
26
|
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
|
PLoS One
|
2011
|
1.23
|
|
27
|
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.
|
Blood
|
2010
|
1.15
|
|
28
|
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
|
Blood
|
2003
|
1.15
|
|
29
|
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
|
Leuk Res
|
2003
|
1.13
|
|
30
|
Eradication of minimal residual disease in hairy cell leukemia.
|
Blood
|
2006
|
1.13
|
|
31
|
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
|
Blood
|
2009
|
1.11
|
|
32
|
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
|
Cancer
|
2003
|
1.06
|
|
33
|
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
|
Cancer
|
2007
|
1.03
|
|
34
|
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
J Clin Oncol
|
2009
|
1.02
|
|
35
|
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
|
Cancer
|
2010
|
1.00
|
|
36
|
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
|
Rev Clin Exp Hematol
|
2002
|
0.98
|
|
37
|
Adolescent and young adult oncology, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.98
|
|
38
|
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
|
Clin Infect Dis
|
2004
|
0.97
|
|
39
|
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
|
Clin Cancer Res
|
2002
|
0.97
|
|
40
|
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
|
Curr Oncol Rep
|
2012
|
0.97
|
|
41
|
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
|
Br J Haematol
|
2010
|
0.96
|
|
42
|
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.
|
Cancer
|
2008
|
0.94
|
|
43
|
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
|
Cancer
|
2014
|
0.94
|
|
44
|
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
|
Blood
|
2005
|
0.93
|
|
45
|
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?
|
Haematologica
|
2011
|
0.92
|
|
46
|
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
|
Blood
|
2002
|
0.92
|
|
47
|
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.92
|
|
48
|
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
|
Cancer
|
2004
|
0.91
|
|
49
|
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center.
|
Cancer Med
|
2014
|
0.91
|
|
50
|
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
|
Cancer
|
2003
|
0.90
|
|
51
|
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.
|
Cancer
|
2011
|
0.89
|
|
52
|
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.
|
Cancer
|
2011
|
0.89
|
|
53
|
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
|
AIDS
|
2002
|
0.89
|
|
54
|
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
|
Cancer
|
2003
|
0.86
|
|
55
|
Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
|
Am J Clin Pathol
|
2009
|
0.85
|
|
56
|
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
|
Blood
|
2003
|
0.84
|
|
57
|
Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma.
|
Mod Pathol
|
2013
|
0.83
|
|
58
|
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
|
Br J Haematol
|
2002
|
0.82
|
|
59
|
Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia.
|
Cancer
|
2011
|
0.82
|
|
60
|
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
|
Cancer
|
2002
|
0.81
|
|
61
|
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
|
Cancer
|
2002
|
0.81
|
|
62
|
New approaches in the treatment of myelofibrosis.
|
Cancer
|
2005
|
0.81
|
|
63
|
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
|
Cancer
|
2011
|
0.80
|
|
64
|
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
|
J Clin Oncol
|
2003
|
0.79
|
|
65
|
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.
|
Am J Hematol
|
2014
|
0.79
|
|
66
|
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.79
|
|
67
|
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
68
|
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
|
Clin Cancer Res
|
2002
|
0.75
|
|
69
|
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Mod Pathol
|
2010
|
0.75
|
|
70
|
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.
|
Invest New Drugs
|
2003
|
0.75
|
|
71
|
Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis.
|
Am J Hematol
|
2013
|
0.75
|
|
72
|
Phase I study of oral topotecan in hematological malignancies.
|
Clin Cancer Res
|
2003
|
0.75
|